Nasdaq:ZLAB
Zai Lab Ltd
Zai Lab Ltd is a biopharmaceutical innovator specializing in antibody-drug conjugate (ADC) technologies for solid tumor treatment.
Key Metrics
Investment Thesis
Bull Case
Zai Lab offers exposure to high-growth oncology assets with a differentiated ADC platform that could yield significant returns upon commercial success. The company's strong cash position of $780.7M provides ample runway to advance its pipeline through critical clinical milestones without immediate dilution. Strategic partnerships and licensing deals offer low-risk revenue streams while the company builds value for its proprietary therapies.
Bear Case
Persistent negative net income of -$175.5M and a deepening retained earnings deficit of -$2.63B signal substantial financial strain and high capital requirements. The company faces intense competition in the crowded ADC space, which may limit pricing power and market penetration for its products. Without imminent product approvals or major milestone payments, investors risk prolonged periods of cash burn without corresponding equity appreciation.
About Zai Lab Ltd
Zai Lab Ltd (NASDAQ: ZLAB) is a global biopharmaceutical company developing proprietary antibody-drug conjugates (ADCs) to treat solid tumors. The company serves markets in the United States, Europe, Asia-Pacific, and Latin America through its commercialization of products like Zaltrap and its pipeline assets. Key revenue drivers include oncology-focused therapies and strategic partnerships with major pharmaceutical firms.
Analysis
Management Discussion
Despite a significant net loss of $175.5M in 2025, Zai Lab achieved substantial year-over-year revenue growth to $460.2M, reflecting successful commercial execution and pipeline expansion. The company maintained a healthy liquidity position with ending cash of $780.7M, allowing it to fund R&D operations while managing operating expenses of $499.1M. However, the widening gap between revenue and net profit underscores the capital-intensive nature of biopharmaceutical development.
Industry Overview
The global biopharmaceutical industry is experiencing rapid innovation in antibody-drug conjugates (ADCs) aimed at treating previously incurable solid tumors. Regulatory bodies worldwide are scrutinizing safety profiles and efficacy data more closely, influencing approval timelines for new oncology therapies. Market dynamics favor companies with proprietary platforms that can navigate complex clinical development landscapes efficiently.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $215.0M | $266.7M | $399.0M | $460.2M |
| Cost of Revenue | $74.0M | $95.8M | $147.1M | $190.5M |
| Gross Profit | $141.0M | $170.9M | $251.9M | $269.6M |
| Operating Expenses | $545.4M | $537.5M | $534.0M | $499.1M |
| Operating Income | $-404.4M | $-366.6M | $-282.1M | $-229.4M |
| R&D | $286.4M | $265.9M | $234.5M | $220.9M |
| G&A | $259.0M | $281.6M | $298.7M | $277.6M |
| Stock-Based Comp | $61.3M | $79.6M | $70.7M | $65.6M |
| D&A | $8.2M | $9.0M | $11.9M | $15.0M |
| Depreciation | $7.7M | $8.4M | $8.6M | $9.1M |
| Amortization | $500.0K | $700.0K | $3.2M | $5.9M |
| Other OpEx | $0 | $-10.0M | $742.0K | $561.0K |
| Non-Operating Income | $-38.9M | $32.0M | $25.0M | $51.0M |
| Interest Expense | $0 | — | $2.3M | — |
| Interest Income | $14.6M | $39.8M | $37.1M | $33.0M |
| Pre-Tax Income | $-443.3M | $-334.6M | $-257.1M | $-178.5M |
| Income Tax | $0 | $0 | $0 | $-2.9M |
| Continuing Ops | $-443.3M | $-334.6M | $-257.1M | $-175.5M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-443.3M | $-334.6M | $-257.1M | $-175.5M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-443.3M | $-334.6M | $-257.1M | $-175.5M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $1.12B | $939.6M | $1.05B | $1.02B |
| Cash & Equivalents | $1.01B | $790.2M | $449.7M | $679.6M |
| Marketable Securities | $0 | $16.3M | $330.0M | $10.0M |
| Accounts Receivable | $40.0M | $59.2M | $85.2M | $106.1M |
| Inventory | $31.6M | $44.8M | $39.9M | $74.7M |
| Prepaid Expenses | $35.7M | $23.0M | $41.5M | $36.7M |
| Other Current Assets | $8.6M | $6.1M | $104.2M | $112.2M |
| Long-Term Assets | $95.8M | $96.7M | $135.3M | $153.1M |
| PP&E (Net) | $57.9M | $53.7M | $48.0M | $47.4M |
| Intangibles | $1.5M | $13.4M | $56.0M | $76.1M |
| Operating Leases | $19.5M | $14.8M | $21.5M | $19.2M |
| LT Investments | $6.4M | $9.2M | $3.1M | — |
| Other LT Assets | $10.5M | $5.5M | $6.7M | $10.4M |
| Total Assets | $1.22B | $1.04B | $1.19B | $1.17B |
| Current Liabilities | $139.8M | $203.1M | $299.4M | $416.2M |
| Accounts Payable | $66.0M | $113.0M | $100.9M | $141.6M |
| Current Leases | $7.0M | $7.1M | $8.0M | $6.3M |
| Other Current Liab | $66.8M | $83.0M | $190.4M | $268.2M |
| Long-Term Liabilities | $34.7M | $37.1M | $45.5M | $40.7M |
| LT Operating Leases | $13.3M | $8.0M | $13.7M | $13.4M |
| Other LT Liab | $21.4M | $29.1M | $31.8M | $27.3M |
| Total Liabilities | $174.5M | $240.2M | $344.9M | $456.9M |
| Shareholders' Equity | $1.05B | $796.1M | $840.9M | $715.5M |
| Retained Earnings | $-1.86B | $-2.20B | $-2.45B | $-2.63B |
| AOCI | $25.7M | $37.6M | $50.5M | $29.7M |
| Total L&E | $1.22B | $1.04B | $1.19B | $1.17B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-443.3M | $-334.6M | $-257.1M | $-175.5M |
| Non-Cash Adjustments | $91.1M | $48.0M | $19.8M | $-72.7M |
| Working Capital Changes | $-15.5M | $88.5M | $22.4M | $97.4M |
| Cash from Operations | $-367.6M | $-198.2M | $-214.9M | $-150.8M |
| Capital Expenditures | $24.6M | $7.2M | $5.7M | $8.1M |
| Cash from Investing | $420.0M | $-10.8M | $-375.2M | $307.9M |
| Cash from Financing | $-1.7M | $-6.4M | $349.9M | $72.4M |
| FX Effect | $-6.3M | $-2.6M | $-310.0K | $478.0K |
| Net Change in Cash | $44.4M | $-218.0M | $-240.5M | $229.9M |
| Beginning Cash | $964.9M | $1.01B | $791.3M | $550.8M |
| Ending Cash | $1.01B | $791.3M | $550.8M | $780.7M |
Frequently Asked Questions
How does Zai Lab Ltd make money?
Primary revenue streams derive from the commercialization of Zaltrap (ziprasertib), licensing fees and royalties from global partners, and ongoing research and development expenditures focused on oncology pipelines.
What are the main risks for ZLAB?
Continued net operating losses and expanding retained earnings deficit of -$2.63B indicating ongoing burn rate; Heavy reliance on successful clinical trial outcomes for future revenue growth; Potential regulatory hurdles or delays in key markets impacting product approvals; Market competition from other ADC developers eroding potential market share.
What is ZLAB's competitive advantage?
Proprietary antibody-drug conjugate (ADC) technology platform with a robust clinical pipeline targeting solid tumors; Strong balance sheet with $780.7M in cash providing strategic flexibility; Established global commercial partnerships reducing initial market entry risks.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.